journal article·2020-02-25Open access

Rapid Intestinal Uptake and Targeted Delivery to the Liver Endothelium Using Orally Administered Silver Sulfide Quantum Dots

Nicholas J. Hunt, Glen P. Lockwood, Frank H. Le Couteur, Peter A. G. McCourt, Nidhi Singla, Sun Woo Sophie Kang, Andrew Burgess, Zdenka Kuncic, David G. Le Couteur, Victoria C. Cogger

ACS Nano· Volume 14· Issue 2

Abstract

Quantum dots (QDs) are used for imaging and transport of therapeutics. Here we demonstrate rapid absorption across the small intestine and targeted delivery of QDs with bound materials to the liver sinusoidal endothelial cells (LSECs) or hepatocytes in vitro and in vivo following oral administration. QDs were radiolabeled with 3H-oleic acid, with a fluorescent tag or 14C-metformin placed within a drug binding site. Three different biopolymer shell coatings were compared (formaldehyde-treated serum albumin (FSA), gelatin, heparin). Passage across the small intestine into mesenteric veins is mediated by clathrin endocytosis and micropinocytosis. 60% of an oral dose of QDs was rapidly distributed to the liver within 30 min, and this increased to 85% with FSA biopolymer coating. Uptake into LSECs also increased 3-fold with FSA coating, while uptake into hepatocytes was increased from 40% to 85% with gelatin biopolymer coating. Localization of QDs to LSECs was confirmed with immunofluorescence and transmission electron microscopy. 85% of QDs were cleared within 24 h of administration. The bioavailability of 14C-metformin 2 h post-ingestion was increased 5-fold by conjugation with QD-FSA, while uptake of metformin into LSECs was improved 50-fold by using these QDs. Endocytosis of QDs by SK-Hep1 cells (an LSEC immortal cell line) was via clathrin- and caveolae-mediated pathways with QDs taken up into lysosomes. In conclusion, we have shown high specificity targeting of the LSEC or hepatocytes after oral administration of QDs coated with a biopolymer layer of FSA or gelatin, which improved the bioavailability and delivery of metformin to LSECs.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Quantum Dots Synthesis And Properties · Infant Nutrition and Health

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

ANZAC Research Institute, Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia

Aging and Alzheimer’s Institute and Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia

Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia

Charles Perkins Centre, The University of Sydney, Sydney, New South Wales 2006, Australia

Department of Medical Biology, University of Tromsø - The Arctic University of Norway, Tromsø 9037, Norway

Nano Institute, The University of Sydney, Sydney, New South Wales 2006, Australia

School of Physics, The University of Sydney, Sydney, New South Wales 2006, Australia

Funding

University of Sydney · National Health and Medical Research Council · Universitetet i Troms? · Sydney Medical School Foundation

References (37)

Show source-provided references
1. 10.1126/science.281.5385.201610.1126/science.281.5385.2016 ↗
2. 10.1126/science.281.5385.201310.1126/science.281.5385.2013 ↗
3. 10.1038/nmat471810.1038/nmat4718 ↗
4. 10.1152/ajpregu.00686.201110.1152/ajpregu.00686.2011 ↗
5. 10.1021/acsnano.8b0494710.1021/acsnano.8b04947 ↗
6. 10.1021/acsnano.8b0965510.1021/acsnano.8b09655 ↗
7. 10.1038/s41467-019-08538-x10.1038/s41467-019-08538-x ↗
8. 10.1002/ijc.3134310.1002/ijc.31343 ↗
9. 10.1021/bc100317910.1021/bc1003179 ↗
10. 10.1002/smll.20140269810.1002/smll.201402698 ↗
11. 10.1021/acsnano.5b0506610.1021/acsnano.5b05066 ↗
12. 10.1021/acs.chemrev.6b0029010.1021/acs.chemrev.6b00290 ↗
13. 10.3390/ijerph12101343510.3390/ijerph121013435 ↗
14. 10.4081/ejh.2018.284110.4081/ejh.2018.2841 ↗
15. 10.1016/j.csbj.2019.07.02110.1016/j.csbj.2019.07.021 ↗
16. 10.1016/j.addr.2018.09.00610.1016/j.addr.2018.09.006 ↗
17. 10.1093/gerona/glz15310.1093/gerona/glz153 ↗
18. 10.1152/ajpgi.00179.201810.1152/ajpgi.00179.2018 ↗
19. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
20. 10.1016/j.addr.2011.12.00910.1016/j.addr.2011.12.009 ↗
21. 10.1021/acsnano.8b0431510.1021/acsnano.8b04315 ↗
22. 10.1016/j.actbio.2017.10.02510.1016/j.actbio.2017.10.025 ↗
23. 10.1021/acsnano.7b0554710.1021/acsnano.7b05547 ↗
24. 10.1016/j.bbamem.2015.11.02210.1016/j.bbamem.2015.11.022 ↗
25. 10.1007/s12272-011-0118-z10.1007/s12272-011-0118-z ↗
26. 10.2165/00003088-200241100-0000510.2165/00003088-200241100-00005 ↗
27. 10.1021/nn900138d10.1021/nn900138d ↗
28. 10.2337/dci15-001310.2337/dci15-0013 ↗
29. 10.1016/0378-5173(95)04259-810.1016/0378-5173(95)04259-8 ↗
30. 10.1152/ajpgi.00069.200810.1152/ajpgi.00069.2008 ↗
31. 10.1038/s41598-017-08259-510.1038/s41598-017-08259-5 ↗
32. 10.1042/bj2003125310.1042/bj20031253 ↗
33. 10.1016/j.cbi.2018.06.03210.1016/j.cbi.2018.06.032 ↗
34. 10.1002/ejic.20160088110.1002/ejic.201600881 ↗
35. 10.1021/nn507118310.1021/nn5071183 ↗
36. 10.1002/jcp.104070011510.1002/jcp.1040700115 ↗
37. 10.1016/j.yexcr.2004.09.01710.1016/j.yexcr.2004.09.017 ↗